Showing results (921-930 of 1,873) with videos related to
Sort By:
Pageof 188
Pulmonary Pharmacology & Therapeutics|February 7, 2018
Selectively targeting prostanoid E (EP) receptor-mediated cell signalling pathways: Implications for lung health and diseaseLeonard F Lebender, Laura Prünte, Nowshin N Rumzhum, et al.Pulmonary Pharmacology & Therapeutics|February 7, 2018
Effect of lipopolysaccharide on the responsiveness of equine bronchial tissueLuigino Calzetta, Paola Rogliani, Elena Pistocchini, et al.Pulmonary Pharmacology & Therapeutics|March 17, 2018
The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adultsPatrick Darken, Paolo DePetrillo, Colin Reisner, et al.Pulmonary Pharmacology & Therapeutics|January 15, 2018
Realising the potential of various inhaled airway challenge agents through improved delivery to the lungsAnne J Lexmond, Dave Singh, Henderik W Frijlink, et al.Pulmonary Pharmacology & Therapeutics|January 17, 2018
Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchusEmmanuel Naline, Stanislas Grassin Delyle, Hélène Salvator, et al.Pulmonary Pharmacology & Therapeutics|March 5, 2018
Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertensionAndreas Krause, Jochen Zisowsky, Jasper DingemansePulmonary Pharmacology & Therapeutics|October 9, 2017
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studiesDean Quinn, Christopher N Barnes, Wayne Yates, et al.Pulmonary Pharmacology & Therapeutics|March 16, 2007
Chronic inhalation of nebulized levalbuterol does not increase mucociliary clearance in healthy subjectsJeffrey C Cleary, Yauel Karmazyn, Peter J Mogayzel, et al.Pulmonary Pharmacology & Therapeutics|November 15, 2006
Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD--a double-blind, randomised, controlled trialT Welte, P Metzenauer, U HartmannPulmonary Pharmacology & Therapeutics|March 22, 2007
Plasma serotonin levels are normal in pulmonary arterial hypertensionDavid J Lederer, Evelyn M Horn, Erika B Rosenzweig, et al.Pageof 188